Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11492798 | 1.00 | ALDH1A1 (0.32) | ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL20214921 | 1.00 | ALDH1A1 (0.32) | ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL8781766 | 0.75 | — | — | |
| SCHEMBL24198251 | 0.73 | — | — | |
| SCHEMBL965841 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL11683267 | 0.73 | — | — | |
| SCHEMBL965842 | 0.73 | — | — | |
| SCHEMBL21240996 | 0.71 | — | — | |
| SCHEMBL9460482 | 0.71 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL9460484 | 0.71 | ALDH1A1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271999-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271999-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-11707531-B2 | Compounds, compositions, and methods for the treatment of disease | F-star Therapeutics, Inc. (GB) | 2023-07-25 | — | — | US | disclosed |
| US-11707531-B2 | Compounds, compositions, and methods for the treatment of disease | F-star Therapeutics, Inc. (GB) | 2023-07-25 | — | — | US | disclosed |
| US-20220152215-A1 | Immunoconjugates Targeting CEA | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-11160874-B2 | Glycoengineered antibody drug conjugates | GENZYME CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200268899-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271999-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | STING1, MAVS, IRF3 | ALDH1A1 3301/4885KDM4E 4097/4885LMNA 2679/4885 |
| US-11160874-B2 | Glycoengineered antibody drug conjugates | CD2BP2, B3GAT3, SIGLEC7 | ALDH1A1 3128/4885KDM4E 3676/4885LMNA 4365/4885 |
| US-11707531-B2 | Compounds, compositions, and methods for the treatment of disease | STING1, MAVS, IRF3 | ALDH1A1 3301/4885KDM4E 4097/4885LMNA 2679/4885 |
| US-20200268899-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | STING1, MAVS, IRF3 | ALDH1A1 3301/4885KDM4E 4097/4885LMNA 2679/4885 |
| US-20220152215-A1 | Immunoconjugates Targeting CEA | CD47, FCGR3B, FCGR1A | ALDH1A1 1242/4885KDM4E 3982/4885LMNA 4839/4885 |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | TLR8, TLR7, TLR9 | ALDH1A1 2748/4885KDM4E 2497/4885LMNA 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.